Cargando…

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azac...

Descripción completa

Detalles Bibliográficos
Autores principales: Tenold, Matthew E., Moskoff, Benjamin N., Benjamin, David J., Hoeg, Rasmus T., Rosenberg, Aaron S., Abedi, Mehrdad, Tuscano, Joseph M., Jonas, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991747/
https://www.ncbi.nlm.nih.gov/pubmed/33777810
http://dx.doi.org/10.3389/fonc.2021.649209
_version_ 1783669232136880128
author Tenold, Matthew E.
Moskoff, Benjamin N.
Benjamin, David J.
Hoeg, Rasmus T.
Rosenberg, Aaron S.
Abedi, Mehrdad
Tuscano, Joseph M.
Jonas, Brian A.
author_facet Tenold, Matthew E.
Moskoff, Benjamin N.
Benjamin, David J.
Hoeg, Rasmus T.
Rosenberg, Aaron S.
Abedi, Mehrdad
Tuscano, Joseph M.
Jonas, Brian A.
author_sort Tenold, Matthew E.
collection PubMed
description Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8–24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML.
format Online
Article
Text
id pubmed-7991747
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79917472021-03-26 Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center Tenold, Matthew E. Moskoff, Benjamin N. Benjamin, David J. Hoeg, Rasmus T. Rosenberg, Aaron S. Abedi, Mehrdad Tuscano, Joseph M. Jonas, Brian A. Front Oncol Oncology Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8–24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML. Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7991747/ /pubmed/33777810 http://dx.doi.org/10.3389/fonc.2021.649209 Text en Copyright © 2021 Tenold, Moskoff, Benjamin, Hoeg, Rosenberg, Abedi, Tuscano and Jonas http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tenold, Matthew E.
Moskoff, Benjamin N.
Benjamin, David J.
Hoeg, Rasmus T.
Rosenberg, Aaron S.
Abedi, Mehrdad
Tuscano, Joseph M.
Jonas, Brian A.
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
title Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
title_full Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
title_fullStr Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
title_full_unstemmed Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
title_short Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
title_sort outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991747/
https://www.ncbi.nlm.nih.gov/pubmed/33777810
http://dx.doi.org/10.3389/fonc.2021.649209
work_keys_str_mv AT tenoldmatthewe outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter
AT moskoffbenjaminn outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter
AT benjamindavidj outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter
AT hoegrasmust outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter
AT rosenbergaarons outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter
AT abedimehrdad outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter
AT tuscanojosephm outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter
AT jonasbriana outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter